Pharmacovigilance and Post-Marketing Compliance in India: The Expanding Obligation Every Pharmaceutical Company Must Understand

Drug approval is the beginning of a Pharmaceutical company’s regulatory obligation — not its culmination. Once a product receives marketing approval, an extensive and ongoing set of post-marketing requirements comes into effect: adverse event reporting, periodic safety update reports, post-marketing surveillance studies, label updates, and increasingly active signal detection and risk management programmes.

For many global Pharmaceutical companies marketing products in India, Pharmacovigilance compliance remains an underinvested area. Spontaneous adverse event reporting is treated as the primary — sometimes sole — post-marketing safety activity. PSURs are submitted reactively, often late. Local signal detection is minimal.

In India’s evolving regulatory environment, Pharmacovigilance is no longer a passive obligation managed through spontaneous reporting. It is an active, system-driven programme that CDSCO expects to see operating continuously — and is increasingly auditing.

1. India’s Pharmacovigilance Framework

NDCT Rules 2019 — Post-Marketing Requirements: Consolidated and strengthened post-marketing requirements for all approved Drugs, including mandatory adverse event reporting timelines, PSUR obligations, and post-marketing surveillance study requirements in specific circumstances.

CDSCO Adverse Event Reporting: MAHs must report: Fatal or life-threatening unexpected SAEs within 15 calendar days; other serious unexpected adverse events within 30 days. Reports are submitted through Vigiflow, operated by the Indian Pharmacopoeia Commission (IPC).

Periodic Safety Update Reports: PSURs are required for all approved Drugs, with frequency determined by approval status and CDSCO requirements. The International Birth Date (IBD) for PSUR scheduling must be confirmed for all India-marketed products.

Risk Management Plans: Required at approval or as a condition of continued approval for products with identified or potential safety concerns.

Post-Marketing Surveillance Studies: CDSCO may require PMS studies as an approval condition. Protocols must be approved and results submitted per CDSCO requirements.

2. The Global-Local Interface

ICSR Flow: Adverse events from India must be integrated into the global ICSR management system. Reports must be assessed for expectedness and seriousness against global reference safety information, with CDSCO expedited reports filed within India-specific timelines.

PSUR Harmonisation: India-specific safety data must be adequately integrated into global PSURs, or India-specific PSURs prepared where CDSCO requirements diverge from global schedules.

Authorised Agent Responsibility: The Indian entity — whether affiliate or authorised agent — bears regulatory responsibility for pharmacovigilance compliance. Many authorised agents are commercial distributors without the Pharmacovigilance capability this responsibility requires.

3. Most Common Pharmacovigilance Compliance Gaps

1. Late or missed expedited adverse events report the most common and directly enforceable failure.
2. PSUR backlogs — not submitted on schedule or submitted without adequate data integration.
3. Inadequate local medical expert oversight — Pharmacovigilance managed administratively without physician supervision.
4. Absent or outdated local Pharmacovigilance SOPs — not adapted to India-specific requirements.
5. Lack of a designated India Pharmacovigilance Contact (PVC).
6. Poor quality medical narratives in expedited reports submitted through Vigiflow.

4. Building a Compliant India Pharmacovigilance Programme

Designate a Qualified PVC: Designate and notify CDSCO of a qualified Pharmacovigilance Contact with appropriate training in CDSCO requirements.

India-Specific ICSR Management Process: Implement ICSR tracking with India-specific report due dates, reporter follow-up requirements, and CDSCO submission timelines.

PSUR Programme Management: Establish a forward-looking PSUR schedule with named ownership, accountability for timeline, and quality for each product.

Annual Pharmacovigilance System Audit: Conduct an annual audit against CDSCO requirements and internal SOPs, with findings feeding into a formal CAPA programme.

Conclusion

Pharmacovigilance compliance in India is no longer a background obligation manageable through minimal resourcing. CDSCO’s enforcement posture is strengthening. Companies that invest in genuinely compliant India Pharmacovigilance programmes protect both their market access and their patients.

CliniExperts provides Pharmacovigilance services including ICSR management, PSUR preparation and submission, Pharmacovigilance system audits, and India Pharmacovigilance programme build-out for global Pharmaceutical companies.